Peptide Schedule
Defensin (HNP-1)30 residuesACYCRIPACIAGERRYGTCIYQGRLWAFCCEach bubble = one amino acid. Size = residue mass. Color = chemical class.Defensin (HNP-1) Dosage Calculator
Human Neutrophil Peptide-1 (HNP-1) belongs to the alpha-defensin family, a class of small cationic antimicrobial peptides that serve as critical effectors of the innate immune system.
50mcg · 3x/week
Summary: Add 2mL BAC water to your 1mg vial. Draw to 10.0 units on a U-100 syringe for a 50mcg dose. This vial will last 20 doses.
Cycle Planner
Defensin (HNP-1) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~3-4 hours (estimated, based on peptide clearance kinetics)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Defensin (HNP-1) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mcg | 3x/week |
| Moderate | 100mcg | Daily |
| Aggressive | 200mcg | Daily |
Note: Human Neutrophil Peptide-1 (HNP-1) is a 30-amino-acid alpha-defensin with a molecular weight of approximately 3,442 Da. It is one of the most abundant antimicrobial peptides found in human neutrophil azurophilic granules, constituting up to 5-7% of total neutrophil protein. HNP-1 forms a triple-stranded beta-sheet structure stabilized by three intramolecular disulfide bonds (Cys2-Cys30, Cys4-Cys19, Cys9-Cys29), which are essential for its antimicrobial and immunomodulatory activity. It is cationic at physiological pH, enabling electrostatic interactions with negatively charged microbial membranes. Research use only — no approved human therapeutic indications exist. Typical research dosing is extrapolated from in vitro antimicrobial concentrations and animal studies.
About Defensin (HNP-1)
Human Neutrophil Peptide-1 (HNP-1) belongs to the alpha-defensin family, a class of small cationic antimicrobial peptides that serve as critical effectors of the innate immune system. HNP-1, along with its close homologs HNP-2 and HNP-3 (which differ only in their N-terminal amino acid), is stored in the azurophilic granules of neutrophils and released upon neutrophil activation during infection or inflammation. The peptide exerts broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, fungi, and enveloped viruses including HIV-1, influenza A, and herpes simplex virus. Its mechanism of direct microbial killing involves electrostatic attraction to negatively charged phospholipid membranes, followed by membrane insertion, pore formation, and disruption of membrane integrity leading to osmotic lysis. Beyond direct antimicrobial effects, HNP-1 serves as a multifunctional immunomodulatory molecule. It acts as a chemoattractant for monocytes, naive T cells, and immature dendritic cells, effectively bridging innate and adaptive immunity. HNP-1 enhances phagocytosis by macrophages, promotes dendritic cell maturation, and stimulates the production of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. It also augments complement activation and can directly opsonize pathogens. Research interest in HNP-1 has expanded to include its potential antitumor properties. Studies have demonstrated that defensins can inhibit tumor cell proliferation and induce apoptosis in certain cancer cell lines, likely through membrane disruption mechanisms similar to their antimicrobial activity. Elevated serum HNP-1 levels have been identified as potential biomarkers in several cancers, including colorectal and bladder cancer, though whether this elevation is protective or merely a marker of neutrophil activation remains under investigation.